Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1

4(66.7%)

Phase 4

2(33.3%)

6Total

Phase 1(4)

Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT01469156Phase 1Completed

Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy

Role: lead

NCT03340610Phase 4Completed

IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab

Role: lead

NCT00837330Phase 1Completed

Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy

Role: lead

NCT02976012Phase 1Unknown

Endolaserless Vitrectomy With Intravitreal IAI for PDR-Related VH

Role: lead

NCT02092532Phase 4Unknown

Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy (RIVAL Trial)

Role: lead

NCT01845844Phase 1Unknown

Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab

Role: lead

All 6 trials loaded